A connection between lung health and kidney function in adults with cystic fibrosis (CF), identifying early urinary markers ...

Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectivelyMore than 3,500 ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

We recently compiled a list of the 12 Best Multibagger Stocks to Buy Right Now. In this article, we are going to take a look ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

LCI proves valuable in monitoring ETI therapy effectiveness for cystic fibrosis patients with minimal FEV1 changes, detecting ...

Krystal Biotech's VYJUVEK, a groundbreaking gene therapy for DEB, achieved $83.8M in Q3 2024 sales. Read why I rate KRYS ...

A $42,000 grant from NASA and INBRE will further CF research, through a collaborative effort spanning to India and the United Kingdom.

The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...

We recently compiled a list of the 10 Stocks That Will Make You Rich In 2025. In this article, we are going to take a look at ...

Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.

Alyftrek is approved as a new treatment for cystic fibrosis, while the FDA expanded the label for Trikafta to include additional genetic mutations.